Jiangsu Hengrui Pharmaceuticals (01276): HRS-8046 tablets approved to initiate clinical trials

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiaries Chengdu Shengdi Pharmaceutical Co., Ltd. and Shanghai Jiangsu Hengrui Pharmaceuticals Co., Ltd. received the Drug Clinical Trial Approval Notice for HRS-8046 tablets approved and issued by the National Medical Products Administration (NMPA), and will initiate clinical trials in the near future. HRS-8046 tablets are an innovative anti-tumor drug independently developed by the company, intended for the treatment of solid tumors carrying KRAS G12D mutations. According to available information, no similar drugs are currently marketed in China or abroad. As of now, cumulative R&D investment in HRS-8046 tablet-related projects is approximately RMB15.4 million (unaudited).